Skip Navigation

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine DFMO in Children with Relapsed, Refractory or Progressive Neuroblastoma

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03794349

Study #:
CMH - ANBL1821

Start Date:
Jun 23, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03794349

View Complete Trial Details & Eligibility at ClinicalTrials.gov